Merck & Company Inc (MRK) — closed signal from May 4, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 2, 2026 — +15.4% at the close.
Predicted vs. what happened
What happened
Reached its target in 52 days.
The thesis — published May 4, 2026
Merck looks like a steady healthcare company with timely, company-specific positives. It beat revenue expectations, nudged guidance higher for 2026, and won FDA approval for an HIV medicine, while a broad drug pipeline helps reduce reliance on Keytruda. Earnings momentum is mixed and near-term price action is weak, so the short-term upside seems realistic but limited.
Primary drivers
- Q1 sales beat and a small 2026 guidance lift
- FDA approval for an HIV drug validates the pipeline
- Wide pipeline helps lower dependence on Keytruda
- Defensive business mix offsets uneven earnings growth
How it played out
MRK: target reached in 52 days
Lyra published a 10% growth thesis at 112.82. The thesis pointed to a first-quarter sales beat, a small guidance lift, approval of an HIV medicine, a wide pipeline, and a defensive business mix. It also noted mixed earnings momentum and weak near-term price action.
The shares reached the 123.21 target in 52 days. They rose to 135.05 on July 28, a 19.7% peak gain, then ended the window at 130.20. The price remained above the target at the close. The thesis played out and exceeded its stated target.
What happened during the window
On May 5, Merck completed its acquisition of Terns Pharmaceuticals. On July 16, Merck announced FDA approval of LIPFENDRA for adults with hypercholesterolemia.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.